In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes

Journal of Infectious Diseases

Volumn 192, Issue 12, 2005, Pages 2112-2116

  Ahlén, Gustaf ^a   Nyström, Jessica ^a   Pult, Irmgard ^a   Frelin, Lars ^a   Hultgren, Catharina ^a   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; STRUCTURAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HEPATITIS C; IMMUNOPRECIPITATION; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; VACCINATION; VIROGENESIS; VIRUS EXPRESSION; VIRUS GENOME;

ADMINISTRATION, CUTANEOUS; ANIMALS; CARRIER PROTEINS; GENES, VIRAL; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; LIVER; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 28844440938     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/498218     Document Type: Article

References (15)

1. Timm J, Lauer GM, Kavanagh DG, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004; 200:1593-604.
2. Seifert U, Liermann H, Racanelli V, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004; 114:250-9.
3. Foy E, Li K, Wang C, et al: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-8.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
5. Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003; 38:1289-96.
6. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 2002; 1:911-6.
7. Brinster C, Muguet S, Lone YC, et al. Different hepatitis C virus non-structural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 2001; 34:1206-17.
8. Encke J, zu Putlitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the non-structural proteins of the hepatitis C virus in a murine model. J Immunol 1998; 161:4917-23.
9. Frelin L, Ahlen G, Alheim M, et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther 2004; 11:522-33.
10. Frelin L, Alheim M, Chen A, et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 2003; 10:686-99.
11. + T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 2001; 82:1299-308.
12. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6:1258-66.
13. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002; 99:13825-30.
14. Zhang G, Gao X, Song YK, et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004; 11:675-82.
15. Isogawa M, Kakimi K, Kamamoto H, Protzer U, Chisari FV. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology 2005; 333:293-300.